These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
728 related articles for article (PubMed ID: 18599488)
41. ABT-737 is highly effective against molecular subgroups of multiple myeloma. Bodet L; Gomez-Bougie P; Touzeau C; Dousset C; Descamps G; Maïga S; Avet-Loiseau H; Bataille R; Moreau P; Le Gouill S; Pellat-Deceunynck C; Amiot M Blood; 2011 Oct; 118(14):3901-10. PubMed ID: 21835956 [TBL] [Abstract][Full Text] [Related]
42. Antimycin A sensitizes cells to TRAIL-induced apoptosis through upregulation of DR5 and downregulation of c-FLIP and Bcl-2. Lee SJ; Kim EA; Song KS; Kim MJ; Lee DH; Kwon TK; Lee TJ Int J Oncol; 2012 Oct; 41(4):1425-30. PubMed ID: 22842544 [TBL] [Abstract][Full Text] [Related]
43. Identification of novel molecular regulators of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in breast cancer cells by RNAi screening. Garimella SV; Gehlhaus K; Dine JL; Pitt JJ; Grandin M; Chakka S; Nau MM; Caplen NJ; Lipkowitz S Breast Cancer Res; 2014 Apr; 16(2):R41. PubMed ID: 24745479 [TBL] [Abstract][Full Text] [Related]
44. 'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737. Lin X; Morgan-Lappe S; Huang X; Li L; Zakula DM; Vernetti LA; Fesik SW; Shen Y Oncogene; 2007 Jun; 26(27):3972-9. PubMed ID: 17173063 [TBL] [Abstract][Full Text] [Related]
45. Tipping the Noxa/Mcl-1 balance overcomes ABT-737 resistance in chronic lymphocytic leukemia. Tromp JM; Geest CR; Breij EC; Elias JA; van Laar J; Luijks DM; Kater AP; Beaumont T; van Oers MH; Eldering E Clin Cancer Res; 2012 Jan; 18(2):487-98. PubMed ID: 22128299 [TBL] [Abstract][Full Text] [Related]
46. Butein sensitizes human hepatoma cells to TRAIL-induced apoptosis via extracellular signal-regulated kinase/Sp1-dependent DR5 upregulation and NF-kappaB inactivation. Moon DO; Kim MO; Choi YH; Kim GY Mol Cancer Ther; 2010 Jun; 9(6):1583-95. PubMed ID: 20515942 [TBL] [Abstract][Full Text] [Related]
47. Dual role of DR5 in death and survival signaling leads to TRAIL resistance in cancer cells. Shlyakhtina Y; Pavet V; Gronemeyer H Cell Death Dis; 2017 Aug; 8(8):e3025. PubMed ID: 29048428 [TBL] [Abstract][Full Text] [Related]
48. Norcantharidin enhances ABT-737-induced apoptosis in hepatocellular carcinoma cells by transcriptional repression of Mcl-1. Zhang S; Li G; Ma X; Wang Y; Liu G; Feng L; Zhao Y; Zhang G; Wu Y; Ye X; Qin B; Lu J Cell Signal; 2012 Sep; 24(9):1803-9. PubMed ID: 22609455 [TBL] [Abstract][Full Text] [Related]
49. Carnosic acid sensitized TRAIL-mediated apoptosis through down-regulation of c-FLIP and Bcl-2 expression at the post translational levels and CHOP-dependent up-regulation of DR5, Bim, and PUMA expression in human carcinoma caki cells. Jung KJ; Min KJ; Bae JH; Kwon TK Oncotarget; 2015 Jan; 6(3):1556-68. PubMed ID: 25596735 [TBL] [Abstract][Full Text] [Related]
50. Overexpression of Par-4 sensitizes TRAIL-induced apoptosis via inactivation of NF-kappaB and Akt signaling pathways in renal cancer cells. Lee TJ; Jang JH; Noh HJ; Park EJ; Choi KS; Kwon TK J Cell Biochem; 2010 Apr; 109(5):885-95. PubMed ID: 20127709 [TBL] [Abstract][Full Text] [Related]
51. Cytotoxicity, drug combinability, and biological correlates of ABT-737 against acute lymphoblastic leukemia cells with MLL rearrangement. Jayanthan A; Incoronato A; Singh A; Blackmore C; Bernoux D; Lewis V; Stam R; Whitlock JA; Narendran A Pediatr Blood Cancer; 2011 Mar; 56(3):353-60. PubMed ID: 21225911 [TBL] [Abstract][Full Text] [Related]
52. Dissecting the roles of DR4, DR5 and c-FLIP in the regulation of geranylgeranyltransferase I inhibition-mediated augmentation of TRAIL-induced apoptosis. Chen S; Fu L; Raja SM; Yue P; Khuri FR; Sun SY Mol Cancer; 2010 Jan; 9():23. PubMed ID: 20113484 [TBL] [Abstract][Full Text] [Related]
53. Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice. Anstee NS; Bilardi RA; Ng AP; Xu Z; Robati M; Vandenberg CJ; Cory S Cell Death Differ; 2019 Jul; 26(7):1316-1331. PubMed ID: 30470795 [TBL] [Abstract][Full Text] [Related]
54. Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis. Simonin K; N'Diaye M; Lheureux S; Loussouarn C; Dutoit S; Briand M; Giffard F; Brotin E; Blanc-Fournier C; Poulain L Apoptosis; 2013 Apr; 18(4):492-508. PubMed ID: 23344663 [TBL] [Abstract][Full Text] [Related]
55. Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation. Kang MH; Wan Z; Kang YH; Sposto R; Reynolds CP J Natl Cancer Inst; 2008 Apr; 100(8):580-95. PubMed ID: 18398104 [TBL] [Abstract][Full Text] [Related]
56. ABT-263 sensitizes TRAIL-resistant hepatocarcinoma cells by downregulating the Bcl-2 family of anti-apoptotic protein. Wang G; Zhan Y; Wang H; Li W Cancer Chemother Pharmacol; 2012 Mar; 69(3):799-805. PubMed ID: 22037880 [TBL] [Abstract][Full Text] [Related]
57. ABT-737 promotes tBid mitochondrial accumulation to enhance TRAIL-induced apoptosis in glioblastoma cells. Cristofanon S; Fulda S Cell Death Dis; 2012 Nov; 3(11):e432. PubMed ID: 23190604 [TBL] [Abstract][Full Text] [Related]
58. Alterations in the Noxa/Mcl-1 axis determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737. Hauck P; Chao BH; Litz J; Krystal GW Mol Cancer Ther; 2009 Apr; 8(4):883-92. PubMed ID: 19372561 [TBL] [Abstract][Full Text] [Related]
59. The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib. Hikita H; Takehara T; Shimizu S; Kodama T; Shigekawa M; Iwase K; Hosui A; Miyagi T; Tatsumi T; Ishida H; Li W; Kanto T; Hiramatsu N; Hayashi N Hepatology; 2010 Oct; 52(4):1310-21. PubMed ID: 20799354 [TBL] [Abstract][Full Text] [Related]
60. TNF-related apoptosis-inducing ligand (TRAIL) frequently induces apoptosis in Philadelphia chromosome-positive leukemia cells. Uno K; Inukai T; Kayagaki N; Goi K; Sato H; Nemoto A; Takahashi K; Kagami K; Yamaguchi N; Yagita H; Okumura K; Koyama-Okazaki T; Suzuki T; Sugita K; Nakazawa S Blood; 2003 May; 101(9):3658-67. PubMed ID: 12506034 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]